Method of treatment with milsaperidone
Described herein is an improved method of treatment with iloperidone or milsaperidone, of a patient in need of such treatment, comprising accounting for an increase in a serum urate level of the patient during treatment with the iloperidone or milsaperidone.
1 . A method of reducing a possibility of an adverse consequence resulting from an increase in a serum urate level in a patient in need of treatment with milsaperidone, and to whom a therapeutically effective amount of milsaperidone is being administered, comprising:
accounting for the increase in the serum urate level of the patient during treatment with the milsaperidone, wherein the accounting comprises monitoring the serum urate level of the patient.
2 . The method of claim 1 , wherein the treatment with milsaperidone results in the increase in the serum urate level of the patient, and
wherein the accounting has the effect of preventing, limiting a frequency of, or limiting a severity of a disease, a condition, or a symptom caused by hyperuricemia or gout.
3 . The method of claim 1 , wherein the monitoring comprises:
obtaining or having obtained a biological sample from the patient; and
testing or having tested the biological sample to determine a concentration of urate in the biological sample.
4 . The method of claim 1 , wherein the monitoring comprises performing the monitoring at one or more milestones selected from:
on or about day 28 of treatment,
on or about day 21 of treatment,
on or about day 14 of treatment,
on or about day 7 of treatment, and
prior to treatment of the patient with the milsaperidone.
5 . The method of claim 1 , wherein the accounting further comprises instructing the patient to ask a doctor or a pharmacist before commencing treatment with the milsaperidone if the patient is taking a prescription drug for gout.
6 . The method of claim 1 , wherein the accounting further comprises informing the patient of one or more symptoms of gout, or asking whether the patient is experiencing joint pain.
7 . The method of claim 1 , wherein the accounting further comprises instructing the patient to reduce or avoid consumption of alcohol, sugar-sweetened beverages and foods, high fructose corn syrup, or purine-rich foods.
8 . The method of claim 1 , wherein the accounting further comprises instructing the patient to reduce or avoid co-administration of the milsaperidone with any of a diuretic, low-dose aspirin, niacin, an immunosuppressant, or cyclosporine.
9 . The method of claim 1 , wherein the accounting further comprises initiating treatment with, or increasing a dose of a urate-lowering medication in an event in which the serum urate level of the patient exceeds about 6 mg/dl.
10 . The method of claim 1 , wherein the accounting further comprises instructing the patient to discuss the treatment with a rheumatologist or a primary care physician.
11 . The method of claim 1 , wherein the accounting further comprises monitoring the patient, or instructing the patient to self-monitor for a presence of a symptom of gout,
wherein the symptom of gout is selected from pain, swelling, discoloration or redness, tenderness to touch, and warmth at an affected joint.
12 . The method of claim 1 , wherein the accounting further comprises:
assessing or having assessed whether the patient is afflicted with any one or more of: obesity, congestive heart failure, a metabolic syndrome, chronic kidney disease, hypertension (high blood pressure), psoriasis, cancer, or a genetic condition associated with increased urate; and
monitoring the patient for development of hypertension, chronic kidney disease, obesity, diabetes, nephrolithiasis, myocardial infarction, or congestive heart failure.
13 . The method of claim 1 , wherein the accounting further comprises instructing the patient to reduce or avoid physical trauma or risk thereof.
14 . The method of claim 1 , wherein the patient in need of treatment with milsaperidone suffers from a disease or disorder selected from schizophrenia, a schizophreniform disorder, bipolar I disorder, acute manic and mixed episodes associated with bipolar I disorder, agitation associated with Alzheimer's Disease, agitation associated with dementia, agitation associated with autism, Parkinson's Disease Psychosis, or another psychotic disease or disorder.